Irritable bowel syndrome; Gut microbiota and probiotic therapy;Síndrome de Intestino Irritable; Papel de la microbiota y probiótico-terapia

Nutricion Hospitalaria

Volumn 31, Issue , 2015, Pages 83-88

  González, Rafael Tojo ^a   Gonzalez, Adolfo Suarez ^b   Madiedo, Patricia Rúas ^c   Mata, Alejo Mancebo ^a   Muñiz, María Pipa ^a   Alonso, Eva Barreiro ^a   Llorente, Francisco Javier Roman ^a   Villar, María Carmen Moro ^b   González, Marta María Arce ^a   Diaz, María Francisca Villegas ^a   Sierra, Eugenia Mosquera ^a   Ruiz, Mónica Ruiz ^a  

^a HOSPITAL DE CABUEÑES   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c DEPARTMENT OF MICROBIOLOGY AND BIOCHEMISTRY OF DAIRY PRODUCTS   (Spain)

Author keywords

Digestive microbiota; Irritable bowel syndrome; Probiotictherapy

Indexed keywords

BIFIDOBACTERIUM; LACTOBACILLUS;

PROBIOTIC AGENT;

ADULT; GASTROINTESTINAL TRACT; HUMAN; INTESTINE FLORA; IRRITABLE BOWEL SYNDROME; MICROBIOLOGY; MICROFLORA;

ADULT; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; MICROBIOTA; PROBIOTICS;

EID: 84923848759     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2015.31.sup1.8713     Document Type: Article

References (53)

1. Wu GD, Lewis JD. Analysis of the human gut microbome and association with disease. Clin Gastroenterol Hepatol 2013; 11:774-777.
2. Aziz A, Dore J, Emmanuel A, et al. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil 2013;25:4-15.
3. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159-176.
4. Fraher MH, O’Toole PW, Quigley EM. Techniques used to characterize the intestinal microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012;9:312-322.
5. Pimentel M, Chang C. Inflammation and microflora. Gastroenterol Clin North Am 2011;40:69.85.
6. Longstreth GF, Thompson WG, Chey WD, et al. Functional Bowel Disorders. Gastroenterology 2006;130:1480-1491.
7. Sperber AD, Dekel R. Irritable bowel syndrome and co-morbid gastrointestinal and extra-gastrointestinal functional syndromes. J Neurogastroenterol Motil 2010;16:113-119.
8. Quigley EM, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012;46:356-366.
9. Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity, and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163-173.
10. Ringel Y, Maharshak N. Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013;305:529-541.
11. Bercik P, Wang L, Verdu EF, et al. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterolgy 2004;127:179-187.
12. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterolgy 2009;136:1979-1988.
13. Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502-1513.
14. Ford AC, Spiegel BM, Talley NJ, et al. Small intestinal bacterial overgrowth in irritable bowel syndrome: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2009;7:1279-1286.
15. Spiegel BM. Questioning the bacterial overgrowth hypothesis of irritable bowel syndrome: an epidemiologic and evolutionary perspective. Clin Gastroenterol Hepatol 2011;9:461-469.
16. Pyleris M, Giamarellos-Bourboulis EJ, Koussoulas B, et al. Small bowel culture confirms the presence of small intestinal bacterial overgrowth in a subset of IBS subjects. Gastroenterology 2011;140(Suppl1):S152.
17. Carroll M, Ringel-Kulka T, Siddle JP, et al. Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:521-530.
18. Maukonen J, Satokari R, Matto J, et al. Prevalence and temporal stability of selected clostridial groups in irritable bowel syndrome in relation to predominant faecal bacteria. J Med Microbiol 2006;55:625-633.
19. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of subgroups of irritable bowel syndrome. Neurogastroenterol Motil 2012;24:31-39.
20. Tack J. Antibiotic therapy for the irritable bowel syndrome. N Engl J Med 2011;364:81-82.
21. Roberfroid M, Gibson GR, Hoyles L, et al. Prebiotic effects: metabolic and health benefits. Br J Nutr 2010;104(Suppl2): S1-S63.
22. Korpela R, Niittynen L. Probiotics and irritable bowel syndrome. Microb Ecol Health Dis 2012;23:18573-18579.
23. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology 2014;146:67-75.
24. Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005;128:1996-2008.
25. Tana C, umesaki Y, Imaoka A, et al. Altered profiles of intestinal microbiota and organic acids may be origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil 2010;22:512-519.
26. Camilleri M, Madsen K, Spiller R, et al. Intestinal barrier function in health and gastrointestinal disease. Neurogastroenterol Motil 2012;24:503-512.
27. Duboc H, Rainteau D, Rajca S, et al. Increase in fecal primary bile acids and dysbiosis in patients with diarrhea-predominant irritable bowel syndrome. Neurogastroenterol Motil 2012;24:513-520.
28. Kamada N, Chen GY, Inohara N, et al. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol 2013;14:685-690.
29. Mayer EA, Savidge T, Shulman RJ. Brain-gut microbiome interactions and functional bowel disorders. Gastroenterology 2014;146:1500-1512.
30. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopatic Constipation. Am J Gastroenterol 2014;109:S2-S26.
31. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopatic constipation: systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547-1561.
32. Ciorba MA. A Gastroenterologist’s guide to probiotics. Clin Gastroenterol Hepatol 2012;10:960-968.
33. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475-486.
34. Guglielmetti S, Mora D, Gschwender M, et al. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life-a double-blind placebo-controlled study. Aliment Pharmacol Ther 2011;33:1123-1132.
35. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.
36. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590.
37. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SDC 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714-2718.
38. Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989;7:23-26.
39. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238.
40. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, doubleblind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-47.
41. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005;147:197-201.
42. Gawronska A, Dziechciarz P, Horvath A. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177-184.
43. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther 2011;33:1302-1310.
44. Hong KS, Kang HW, Im JP, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver 2009;3:101-107.
45. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38:S104-106.
46. Kajander K, Hatakka K, Poussa T, et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-394.
47. Kajander K, Myllyluoma E, Rajilic-Stojanovic M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57.
48. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.
49. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687-696.
50. Guandalini S, Magazzu G, Chiaro A, et al. VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr 2010;51: 24-30.
51. Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009;29:97-103.
52. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. American College of Gastroenterology Task Force on Irritable Bowel Syndrome. An evidence-based systematic review on the management of irritable bowel syndrome. Am J Gastroenterol 2009;104 (suppl 1):S1-S35.
53. Steidler L, Neirynck S. Insitu delivery of therapeutic proteins by recombinant Lactococcus lactis. J Microbiol 2003;41: 63-72.